Featured

Prime time: secondary prolonged DC priming boosts high-affinity T cell responses

After initial priming through interaction with dendritic cells (DCs), CD8+ T cells disengage and migrate, but little is known about how cytokine signals are transmitted or received by these cells for differentiation during this migration. Jobin...

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

Nieto et al. reported favorable safety profiles and preliminary activity of cord blood-derived cytokine-pre-activated and expanded NK cells pre-complexed with AFM13 – a CD30/CD16A bispecific antibody ...

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

Wermke et al. reported interim data from a phase 1 dose-escalation trial of IMA203 – PRAME-directed autologous TCR T cell therapy – in HLA-A*02+ patients with PRAME+ recurrent and/or refractory solid ...

Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse

Heras-Murillo et al. treated mice with tumor cell lysate-loaded syngeneic splenic selected cDC populations. cDC1-based vaccines induced cancer-specific Teff and Tmem cells, and reduced tumor burden i...

Succinate-loaded tumor cell-derived microparticles reprogram tumor-associated macrophage metabolism

To reprogram M2-like macrophages in the TME and enhance their antitumor efficacy, Lu and Li et al. used electroporation to load tumor cell membrane-derived microparticles with succinate (SMPs), which ...

See all for this week

Previous Digests

Unraveling the role of soluble CTLA-4

April 16, 2025

CTLA-4 is a well established immune checkpoint with a key a role in limiting autoimmunity, but it exists in both membrane-bound (mCTLA-4) and soluble (sCTLA-4) forms, and the different sources, kinetics, and functions of sCTLA-4 in particular are not...

KEYSTONE SYMPOSIA: Cancer Immunotherapy: Clinical Lessons to New Modalities

April 9, 2025

The ACIR team attended the Keystone Symposia on Cancer Immunotherapy: Clinical Lessons to New Modalities held on March 16-19, 2025 in Banff, AB, Canada. This week’s extensive special feature covers select talks from the conference. We have organized the...

Translation dysregulation in cancer produces targetable antigens

April 2, 2025

Dysregulation of translation and protein synthesis is often observed in cancer, but whether this results in the production of targetable antigens has not been fully explored. Investigating this possibility, Weller, Bartok, and McGinnis et al. used CRISPR-Cas9 to study...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ute Burkhardt

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.

— Nir Hacohen, PhD

Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT

Testimonials